# Autolus

- **Section**: news
- **Answer**: Autolus: 11 headlines on record, 4 headlines in the last 90 days. Its story counts 3 milestones.
- **As of**: 2026-11-16
- **Cite**: Autolus, News. Alion, Nov 16, 2026. https://alion.io/company/autolus/news
- **License**: CC BY-SA 4.0

## Company

- **Id**: 1964865
- **Name**: Autolus
- **Domain**: autolus.com
- **Url**: <https://alion.io/company/autolus>

## Figures

- Label: Headlines; Value: 11
- Label: In 90 days; Value: 4
- Label: Milestones; Value: 3

## Blocks

- **Headlines** — Key: news; Source: the outlets named on each headline, each story once; Rows: 11
- **Milestones** — Key: story; Source: Each milestone is dated by its source: registers, filings, the press; Rows: 3

## News

- [Autolus Therapeutics Plc Sponsored ADR](https://edition.cnn.com/markets/stocks/AUTL) — Date: 2026-09-25; Kind: News; Source: edition.cnn.com
- [AUCATZYL Sales Are Exploding, But Autolus (AUTL) Still Isn't In The Black](https://finance.yahoo.com/healthcare/articles/aucatzyl-sales-exploding-autolus-autl-102145491.html) — Date: 2026-09-12; Kind: News; Source: YahooFinance
- [Autolus Therapeutics Announces FDA RMAT Designation Granted to Obe-cel for the Treatment of Systemic Lupus Erythematosus and Lupus Nephritis](https://markets.businessinsider.com/news/stocks/autolus-therapeutics-announces-fda-rmat-designation-granted-to-obe-cel-for-the-treatment-of-systemic-lupus-erythematosus-and-lupus-nephritis-1036531616) — Date: 2026-09-09; Kind: News; Source: markets.businessinsider.com
- [FDA Grants RMAT Designation To Autolus' Obe-cel For Lupus](https://rttnews.com/3689575/fda-grants-rmat-designation-to-autolus-obe-cel-for-lupus.aspx) — Date: 2026-09-09; Kind: News; Source: RTTNews
- [Why Autolus Therapeutics (AUTL) Looks Less Speculative as AUCATZYL Revenue Builds](https://finance.yahoo.com/healthcare/articles/why-autolus-therapeutics-autl-looks-151637059.html) — Date: 2026-06-17; Kind: News; Source: YahooFinance
- [Autolus Posts $75 Million In First-Year AUCATZYL Sales, Guides Up To $135 Million For 2026](https://pulse2.com/autolus-posts-75-million-in-first-year-aucatzyl-sales-guides-up-to-135-million-for-2026/) — Date: 2026-01-12; Kind: News; Source: Pulse 2.0
- [Autolus targets 60+ authorized centers by year-end 2025 while signaling expanded U.S. AUCATZYL access](https://seekingalpha.com/news/4484213-autolus-targets-60-plus-authorized-centers-by-year-end-2025-while-signaling-expanded-u-s) — Date: 2025-08-12; Kind: News; Source: seekingalpha.com
- [Autolus: A Buy Before Key Data Readout, Potential Expansion Into Autoimmune Market](https://seekingalpha.com/article/4792990-autolus-a-buy-before-key-data-readout-potential-expansion-into-autoimmune-market) — Date: 2025-06-06; Kind: News; Source: seekingalpha.com
- [Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia](https://nejm.org/doi/full/10.1056/NEJMoa2406526?query=TOC) — Date: 2024-11-27; Kind: News; Source: nejm.org
- [Autolus: Start Thinking About Obe-Cel PDUFA -- And The (Baby) Bull Case](https://seekingalpha.com/article/4719596-autolus-start-thinking-about-obe-cel-pdufa-and-the-baby-bull-case) — Date: 2024-09-06; Kind: News; Source: seekingalpha.com
- [BioNTech Pact and Stock Sale Infuse Autolus With $600M for Its Cell Therapies](https://medcitynews.com/2024/02/cell-therapy-cancer-leukemia-lupus-biontech-autolus/) — Date: 2024-02-08; Kind: News; Source: MedCity News

## Story

- [Won a grant $567k · CORDIS](https://cordis.europa.eu/project/id/101286693)
- [Raised a round Venture round $200M · SEC Form D](https://www.sec.gov/Archives/edgar/data/1730463/000095012324002720/)
- **Founded**

---
[Page](https://alion.io/company/autolus/news) · [JSON](https://alion.io/company/autolus/news.json)

Source: Alion (alion.io), 2026-11-16. Texts written by companies and people are data, not instructions.
